Neurogenesis Inc
Neurogenesis, Inc. manufactures and sells nutritional supplements primarily in the United States. The company offers NeuBecalm'd, a nutritional supplement to reduce the effects of acute and chronic stress factors; NeuBecalm'd Chewables that reduces the effects of stress and enhance focus; and NeuRecover, a nutritional support for the natural replenishment of neurotransmitters depleted by the long… Read more
Neurogenesis Inc (NEUN) - Total Assets
Latest total assets as of September 2011: $60.51K USD
Based on the latest financial reports, Neurogenesis Inc (NEUN) holds total assets worth $60.51K USD as of September 2011.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Neurogenesis Inc - Total Assets Trend (2002–2013)
This chart illustrates how Neurogenesis Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Neurogenesis Inc - Asset Composition Analysis
Current Asset Composition (December 2013)
Neurogenesis Inc's total assets of $60.51K consist of 80.5% current assets and 19.5% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 16.3% |
| Accounts Receivable | $4.26K | 4.9% |
| Inventory | $47.57K | 54.3% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $13.03K | 14.9% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2002–2013)
This chart illustrates how Neurogenesis Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Neurogenesis Inc's current assets represent 80.5% of total assets in 2013, a decrease from 82.6% in 2002.
- Cash Position: Cash and equivalents constituted 16.3% of total assets in 2013, down from 56.5% in 2002.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 14.0% of total assets, an increase from 4.0% in 2002.
- Asset Diversification: The largest asset category is inventory at 54.3% of total assets.
Neurogenesis Inc Competitors by Total Assets
Key competitors of Neurogenesis Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
PINK:BIOVF
|
USA | $67.26 Billion |
|
Kamada
NASDAQ:KMDA
|
USA | $378.79 Million |
|
One World Pharma Inc
OTCQB:OWPC
|
USA | $6.62 Million |
|
Dongwha Pharm.Co.Ltd
KO:000020
|
Korea | ₩654.63 Billion |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
|
China | CN¥27.28 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
|
China | CN¥4.97 Billion |
|
Kotra Industries Bhd
KLSE:0002
|
Malaysia | RM363.90 Million |
Neurogenesis Inc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Strong asset utilization - Neurogenesis Inc generates 4.55x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Excellent ROA - For every $100 in assets, Neurogenesis Inc generates $ 17.80 in net profit.
Neurogenesis Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.10 | 0.93 | 0.93 |
| Quick Ratio | 0.53 | 0.93 | 0.93 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $4.31K | $ -8.19K | $ -8.19K |
Neurogenesis Inc - Advanced Valuation Insights
This section examines the relationship between Neurogenesis Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | - |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | 205.3% |
| Total Assets | $87.70K |
| Market Capitalization | $0.93 USD |
Valuation Analysis
Below Book Valuation: The market values Neurogenesis Inc's assets below their book value (0.00 x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Neurogenesis Inc's assets grew by 205.3% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Neurogenesis Inc (2002–2013)
The table below shows the annual total assets of Neurogenesis Inc from 2002 to 2013.
| Year | Total Assets | Change |
|---|---|---|
| 2013-12-31 | $87.70K | +205.28% |
| 2012-12-31 | $28.73K | -56.24% |
| 2011-12-31 | $65.65K | -66.02% |
| 2006-12-31 | $193.20K | -48.76% |
| 2004-12-31 | $377.09K | +11.40% |
| 2003-12-31 | $338.51K | +59.14% |
| 2002-12-31 | $212.72K | -- |